Context Therapeutics News and Activities
Presence
Context Therapeutics is a biotechnology company that develops cancer treatments. Its main services include drug research and clinical development for patients, healthcare providers, and partners in oncology.
Context Therapeutics products and services overview:
- Cancer therapies
- Drug discovery
- Clinical development
- Oncology research
Revenue: ~$0 million
Employees: 30
Headquarters: Philadelphia, United States (USA)
Context Therapeutics is one of the...
Context Therapeutics is a company listed under the stock ticker CNTX (US).
Executives
View the org chart displaying its 20 main executives
Most searched biographies at Context Therapeutics
- Martin Lehr, Chief Executive Officer and Director
- Jennifer Evans Stacey, Director
- Andy Pasternak, Chairman of the Board
Create your alert
to follow the executive moves at Context Therapeutics.
Biotechnology
Context Therapeutics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- The new name of ChemoTech is Neem’s Hill. (posted on July 15 2026).
- Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
- MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
Popular contacts in Biotechnology
News
Press releases by Context Therapeutics
- Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes | Context Therapeutics Inc.
- Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Context Therapeutics Inc.
- Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Context Therapeutics Inc.
- Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 | Context Therapeutics Inc.
- Context Therapeutics to Present at the Jefferies Global Healthcare Conference | Context Therapeutics Inc.
- Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | Context Therapeutics Inc.
- Context Therapeutics Reports First Quarter 2026 Operating and Financial Results | Context Therapeutics Inc.
- Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer | Context Therapeutics Inc.
- Context Therapeutics Reports Full Year 2025 Operating and Financial Results | Context Therapeutics Inc.
- Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 | Context Therapeutics Inc.
- View more press releases Close
Social media about Context Therapeutics
- Context Therapeutics on Wikipedia, Google News & Yahoo Finance
- Context Therapeutics on LinkedIn, X (Twitter) & YouTube
